May 22, 2025 07:43AM
Mar 21, 2023 07:00AM
Mar 21, 2023 07:00AM
Dec 15, 2022 04:02PM
Dec 15, 2022 04:01PM
Dec 15, 2022 04:01PM
Dec 14, 2022 04:01PM Vigil Neuroscience (VIGL) Announces First Patient Dosed in the IGNITE Phase 2 Clinical Trial to Evaluate VGL101 in Patients with ALSP
Dec 14, 2022 04:01PM
Dec 14, 2022 04:01PM
Nov 10, 2022 07:00AM
Nov 10, 2022 07:00AM
Nov 2, 2022 07:00AM
Nov 2, 2022 07:00AM
Nov 2, 2022 07:00AM Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP
Nov 1, 2022 07:00AM
Nov 1, 2022 07:00AM
Nov 1, 2022 07:00AM
Aug 8, 2022 07:00AM
Aug 8, 2022 07:00AM
Aug 1, 2022 07:02AM
Aug 1, 2022 07:00AM Vigil Neuroscience Presents Preclinical Data on VGL101 for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) and Clinical Phenotype of ALSP at Alzheimer's Association Int
Aug 1, 2022 07:00AM
Jul 28, 2022 07:04AM
Jul 28, 2022 07:00AM
Jul 28, 2022 07:00AM
May 12, 2022 07:00AM
May 12, 2022 07:00AM
Apr 20, 2022 07:03AM Vigil Neuroscience (VIGL) Appoints Mary Thistle to its Board
Apr 20, 2022 07:00AM
Apr 20, 2022 07:00AM
Mar 25, 2022 06:30AM
Mar 25, 2022 06:30AM
Mar 25, 2022 06:30AM
Jan 11, 2022 04:01PM
Jan 11, 2022 04:01PM Vigil Neuroscience Announces Closing of Initial Public Offering
Jan 7, 2022 11:44AM
Jan 7, 2022 05:57AM
Jan 6, 2022 11:07PM
Jan 6, 2022 11:07PM
Jan 4, 2022 04:52PM
Jan 3, 2022 06:35AM
Nov 19, 2021 04:15PM Vigil Neuroscience (VIGL) Files IPO Registration Statement

118,853 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All